SHORT COMMUNICATION

Determination of respiratory syncytial virus epidemic seasons by using 95% confidence interval of positivity rates, 2011–2021, Germany

Wei Cai1 ⋆ | Ralf Dürrwald2,3 ⋆ | Barbara Biere2 ⋆ | Brunhilde Schweiger2 ⋆ | Walter Haas1 | Thorsten Wolff2 | Silke Buda1 | Janine Reiche2,3 ⋆

1Unit 36, Respiratory Infections, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
2Unit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre, Robert Koch Institute, Berlin, Germany
3Unit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, Consultant Laboratory for RSV, PIV and HMPV, Robert Koch Institute, Berlin, Germany

Correspondence
Janine Reiche, Unit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, Consultant Laboratory for RSV, PIV and HMPV, Robert Koch Institute, Seestraße 10, D-13353 Berlin, Germany.
Email: reichej@rki.de
Silke Buda, Unit 36, Respiratory Infections, Department of Infectious Disease Epidemiology, Robert Koch Institute, Seestraße 10, D-13353 Berlin, Germany.
Email: budas@rki.de

Abstract
Based on our national outpatient sentinel surveillance, we have developed a novel approach to determine respiratory syncytial virus (RSV) epidemic seasons in Germany by using RSV positivity rate and its lower limit of 95% confidence interval. This method was evaluated retrospectively on nine RSV seasons, and it is also well-suited to describe off-season circulation of RSV in near real time as observed for seasons 2020/21 and 2021/22 during the COVID-19 pandemic. Prospective application is of crucial importance to enable timely actions for health service delivery and prevention.

KEYWORDS
acute respiratory infection, confidence interval, epidemic season, respiratory syncytial virus, surveillance

1 | INTRODUCTION

Respiratory syncytial virus (RSV) is the major cause of acute lower respiratory tract infection (ALRI) in children. Globally, 33.1 million episodes of ALRI were caused by RSV infection which resulted in estimated 3.2 million hospital admissions, and 59,600 in-hospital deaths in children younger than 5 years in 2015. To date, no approved vaccine against RSV exists. In order to prevent severe ALRI due to RSV, passive immunoprophylaxis with palivizumab can be carried out in infants at high risk.

RSV causes seasonal epidemics worldwide. In Europe, an average RSV season starts in the beginning of December, peaks in early February, and continues until early April. So far, there is no accepted method for defining start and end of RSV epidemic seasons, although few methods have been recently recommended.

In Germany, RSV activities were commonly investigated within our national outpatient sentinel surveillance, and RSV epidemic seasons have been determined retrospectively. This study aimed to establish a prospective, sensitive, and sustainable method to determine the start and end of RSV epidemic seasons on population level.

2 | RSV DETECTIONS

Specimens (nasal or throat swabs, and nasopharyngeal swabs) from outpatients of five age groups (0–4, 5–14, 15–34, 35–59, and...
>60 years old) with acute respiratory infection (ARI) were collected year-round by physicians participating in the national sentinel surveillance and sent to the Robert Koch Institute (RKI, Berlin, Germany) where they were prospectively tested for RSV by real-time reverse transcription PCR. From 2011/12 to 2019/20, a total of 33,351 RSV positives were detected within calendar weeks 40 to 20, the time of regular RSV activity in Germany. Although RSV detections were observed in all age groups, median positivity rates (PR) were highest among young children aged 0 to 4 years (Figure 1). Further, median RSV PR in young children were 2.6-fold higher compared with median PR in all ages (nonparametric Mann–Whitney U test, \( P = .0003 \), Stata® version 17). Because robust and reliable RSV surveillance data are of crucial importance, RSV PR among 0 to 4 years old children was selected for the determination of RSV epidemic season solely.

3 | DETERMINATION OF RSV SEASONALITY

Among children aged 0 to 4 years, the number of RSV positive and negative tested cases were sorted by season and calendar week (collection date, if not available then received date). For each calendar week, the PR and the associated 95% confidence interval (95% CI) were calculated with Stata® version 17. Both RSV PR and the corresponding 95% CI were plotted against the calendar week of the seasons 2011/12 to 2021/22 (Figure 2). A high PR can be associated with a low number of investigated (received) samples and single RSV positive detections and will moreover result in a less precise estimate of the 95% CI with probably reduced lower limit of 95% CI (Figure 2). To circumvent such unlikely high RSV PRs, the lower limit of the 95% CI was used herein to determine the RSV epidemic season. Within an iterative process, manually different thresholds were thoroughly evaluated to determine the cut off for the start and end of retrospective RSV epidemic seasons. Then, the start of the RSV epidemic season was defined as the first of two consecutive weeks in which the lower limit of 95% CI of the RSV PR exceeds 5% among 0 to 4 years old children. The RSV epidemic season ends by the week that precedes first of two consecutive weeks, in which the lower limit of 95% CI of the RSV PR drops below 5%. One gap week below the threshold was allowed.

Among 0 to 4 years old children, an RSV epidemic season could be retrospectively assigned to each season from 2011/12 to 2019/20 (Figures 2 and 3). The median start of RSV epidemic seasons was in calendar week 50 (range: 45–3), peaked in median in calendar week 8 (range: 51–10), and ended in median in week 12 (range: 10–18). The median length of the RSV season was 15 weeks (range: 13–18).

In contrast, during the COVID-19 pandemic starting in calendar week 11 in 2019/20, there was almost no RSV detected within the time of RSV epidemics as observed for the seasons 2011/12 to 2019/20 (median weeks 50–12) among 0 to 4 years old children. Between calendar weeks 9 and 30 in 2020/21, only sporadic RSV cases occurred. The number of RSV cases and the corresponding RSV PR increased in calendar week 31. According to our definition of the timing of an RSV epidemic season, in 2020/21, the RSV season began in calendar week 35 (PR: 13%, 95% CI: 5.2–24.1) and continued until calendar week 50 (PR: 26%, 95% CI: 15.3–39.0) in season 2021/22 (Figures 2 and 3).

4 | ETHICAL STATEMENT

The German national ARI sentinel surveillance has been approved by the Charité-Universitätsmedizin in Berlin Ethical Board (Reference EA2/126/11).
5 | DISCUSSION

Using German national ARI sentinel surveillance data of 0–4 aged outpatients, we have developed a novel approach to describe RSV epidemic seasons both retrospectively and prospectively. Although sentinel practitioners were encouraged to continuously collect specimens year-round, the number of specimens sent to RKI was considerably low between calendar weeks 21 and 39 for seasons 2011/12–2018/19. A low sample size will result in a high RSV PR, which is most likely far away from the “true value.” The width of the 95% CI increases, and the lower limit of 95% CI decreases correspondingly as the sample size decreases. Thus, the lower limit of 95% CI of the RSV PR was used herein for the determination of RSV epidemic season. This is similar to the determination of the influenza seasonality in Germany where the cutoff was set 10% as the lower limit of 95% CI of PR.

Based on this 95% CI method, RSV epidemic seasons 2011/12 to 2019/20 started in median in calendar week 50 (range: 45–3) and ended in median in week 12 (range: 10–18) in Germany. Calculations for the determination of RSV epidemic seasons on the same setting applying the 1.2% method defined a similar start (week 48) or end (week 15) as determined by our novel approach. In addition, the median length of the RSV epidemic season in Germany was 15 weeks (range: 13–18) as determined in this study, and 17 (11–22) weeks as calculated with the retrospective 1.2% threshold. The median length of RSV epidemic seasons based on sentinel surveillance systems in the European Union/European Economic Area was 16 (range: 9–24) weeks.

For a further comparison, we analyzed our sentinel data with a threshold of a weekly percentage of 3%, which resulted in a comparative earlier start (week 47, range: 45–50) and longer duration (length 22 weeks, range: 20–26) of RSV epidemic season. This might be most likely caused by low sample numbers at the start and end of the RSV season. For the same reason, we could not apply the 10-fold baseline method, a near real-time approach, to our setting, because no threshold could be determined. Further, we examined our data set by the moving epidemic method, which has been recently validated for characterization of RSV epidemics in the Netherlands.

Based on optimum slope parameter of 2.2, the obtained average epidemic start week of 51 and average week length of 14 confirmed calculations by the 95% CI method.

As for many other European countries, in the winter season 2020/2021, there were almost no RSV cases detected in Germany. Reasons might be seen in the COVID-19 pandemic and associated non-pharmaceutical interventions (NPI) strategies, which suppressed transmission not only of SARS-CoV-2 but also of other respiratory viruses including RSV. Efforts in vaccination campaigns against SARS-CoV-2 led to loosening of NPI interventions in many fields since May 2021, thus leading to an increase of RSV starting late in calendar week 35 in season 2020/21. Group of 0 to 4 years old children was most affected in season 2020/21 and 2021/22, respectively, thus confirming convincingly that this age group provides reliable data for determination of RSV epidemic seasons in our sentinel surveillance.

6 | CONCLUSIONS

We have developed a method that defines the start and end of an RSV epidemic season. The 95% CI method is reliable working on consistent sentinel data as well as in systems with a small weekly sample size. On a basis of timely receipt and testing of specimens for RSV, this method can be used in near real time, which had been proven in this unusual RSV off-season circulation in seasons 2020/21 and 2021/22 during the COVID-19 pandemic. Prospective use enables necessary flexible and timely actions in RSV prevention and control on population level.

ACKNOWLEDGMENTS

We are indebted to the patients, their families, and the sentinel clinicians who made these investigations possible. We thank Nathalie Tollard, Uwe Kozian, Heike Fischer, Mareen Adam, Anneliese Schindel, Bettina Mischke, Ingrid Zadow, Carmen Karstädt-Schulze, Jeannette Milde, Susi Hafemann, Ute Preuß, and Kerstin Prahm for excellent technical assistance, as well as Bernd Reinhardt and Michael Herzhoff for outstanding data management support.
AUTHOR CONTRIBUTIONS

Wei Cai: Conceptualization; data curation; formal analysis; investigation; methodology; project administration; validation; visualization.
Ralf Dürrwald: Conceptualization; investigation; resources; supervision.
Barbara Biere: Data curation; investigation; methodology.
Brunhilde Schweiger: Conceptualization; investigation; resources; supervision. Walter Haas: Resources; supervision. Thorsten Wolff: Conceptualization; resources; supervision. Silke Buda: Conceptualization; investigation; methodology; project administration; resources; supervision; validation. Janine Reiche: Conceptualization; data curation; formal analysis; investigation; methodology; project administration; resources; supervision; validation; visualization.

ORCID

Wei Cai https://orcid.org/0000-0001-8650-4880
Ralf Dürrwald https://orcid.org/0000-0002-3432-0438
Barbara Biere https://orcid.org/0000-0001-6988-3735
Brunhilde Schweiger https://orcid.org/0000-0003-4847-9199
Janine Reiche https://orcid.org/0000-0003-2541-1095

REFERENCES

1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545-1555. doi:10.1016/S0140-6736(10)60206-1
2. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946-958. doi:10.1016/S0140-6736(17)30938-8
3. Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol. 2019;17(4):233-245. doi:10.1038/s41579-019-0149-x
4. Groothuis JR, Hoopes JM, Hemming VG. Prevention of serious respiratory syncytial virus-related illness. II: immunoprophylaxis. Adv Ther. 2011;28(2):110-125. doi:10.1007/s12265-010-0101-y
5. Bloom-Feshbach K, Alonso WJ, Charu V, et al. Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review. PLoS ONE. 2013;8(2):e54445. doi:10.1371/journal.pone.0054445
6. Broberg EK, Waris M, Johansen K, Snacken R, Penttinen P. European Influenza Surveillance Network. Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European countries, 2010 to 2016. Euro Surveill. 2018;23(5):17-00284. doi:10.2807/1560-7917.ES.2018.23.5.17-00284
7. Teirlinck AC, Broberg EK, Stuwtz Berg A, et al. Recommendations for respiratory syncytial virus surveillance at the national level. Eur Respir J. 2021;58(3):2003766. doi:10.1183/13993003.03766-2020
8. Reiche J, Schweiger B. Genetic variability of group A human respiratory syncytial virus strains circulating in Germany from 1998 to 2007. J Clin Microbiol. 2009;47(6):1800-1810. doi:10.1128/JCM.02286-08
9. Cai W, Tolksdorf K, Hirve S, et al. Evaluation of using ICD-10 code for respiratory syncytial virus surveillance. Influenza Other Respi Viruses. 2019;14(6):630-637. doi:10.1111/irv.12665
10. Oh DY, Buda S, Biere B, et al. Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January - September 2020: analysis of national surveillance data. Lancet Reg Health Eur. 2021;6:100112. doi:10.1016/j.lanepi.2021.100112
11. European Centre for Disease Prevention and Control (ECDC). Novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK—sixth update 2020. https://www.ecdc.europa.eu/sites/default/files/documents/RR40—sixth-update-Outbreak-of-novel-coronavirus-disease-2019-COVID-19.pdf
12. Hazra A. Using the confidence interval confidently. J Thorac Dis. 2017;9(10):4125-4130. doi:10.21037/jtd.2017.09.14
13. Midgley CM, Haynes AK, Baumgardner JL, et al. Determining the seasonality of respiratory syncytial virus in the United States: the impact of increased molecular testing. J Infect Dis. 2017;216(3):345-355. doi:10.1093/infdis/jix275
14. Vos LM, Teirlinck AC, Lozano JE, et al. Use of the moving epidemic method (MEM) to assess national surveillance data for respiratory syncytial virus (RSV) in the Netherlands, 2005 to 2017. Euro Surveill. 2019;24(20):1800469. doi:10.2807/1560-7917.ES.2019.24.20.1800469
15. van Summeren J, Meijer A, Aspelund G, et al. Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter? Euro Surveill. 2021;26(29):2100639. doi:10.2807/1560-7917.ES.2021.26.29.2100639

How to cite this article: Cai W, Dürrwald R, Biere B, et al. Determination of respiratory syncytial virus epidemic seasons by using 95% confidence interval of positivity rates, 2011-2021, Germany. Influenza Other Respi Viruses. 2022;16(5):854-857. doi:10.1111/irv.12996